The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Metsera Inc. MTSR, a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of ...

The data showed that MET-097i helped participants lose weight, with some shedding up ... so far, limited. Metsera, Inc. (NASDAQ:MTSR) is also one of the 10 stocks insiders spent the most money ...

MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is expanding its presence in the weight loss and metabolic disease sector through a strategic collaboration with Metsera, Inc., announced in October 2024.

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...